Galapagos NV
GLPG | BR
Overview
Corporate Details
- ISIN(s):
- BE0003818359
- LEI:
- 549300QKJ78IY0IOV655
- Country:
- Belgium
- Address:
- Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen
- Website:
- https://www.glpg.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Galapagos NV is a biotechnology company dedicated to transforming patient outcomes through scientific innovation. Following a strategic restructuring, the company now focuses on developing and commercializing novel cell therapies, particularly in oncology. It leverages a unique, decentralized, and scalable manufacturing platform designed to rapidly deliver CAR-T therapies to patients. Galapagos is actively growing its pipeline through strategic acquisitions and partnerships while seeking to divest its legacy small molecule assets. The company's mission is to develop life-changing treatments to provide patients with more years of life and improved quality of life.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Galapagos NV.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 07:36 |
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
|
Dutch | 203.1 KB | |
| 2025-08-08 07:36 |
Share Issue/Capital Change
Galapagos Creates New Subscription Right Plan
|
English | 201.6 KB | |
| 2025-08-07 00:00 |
Remuneration Information
Galapagos_PR_07082025_ENG.pdf
|
English | 208.3 KB | |
| 2025-08-07 00:00 |
Remuneration Information
Galapagos_PR_07082025_NL.pdf
|
Dutch | 215.6 KB | |
| 2025-08-07 00:00 |
Report Publication Announcement
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_ENG_FINAL_Website(…
|
English | 262.4 KB | |
| 2025-08-07 00:00 |
Share Issue/Capital Change
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_NL_FINAL_Website(i…
|
Dutch | 379.8 KB | |
| 2025-08-06 08:13 |
Regulatory News Service
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) D…
|
Dutch | 101.6 KB | |
| 2025-08-06 08:13 |
Legal Proceedings Report
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) D…
|
English | 235.6 KB | |
| 2025-08-06 07:30 |
Legal Proceedings Report
Galapagos Press Release_RMAT Designation_GLPG5101_ENG_final.pdf
|
English | 235.6 KB | |
| 2025-08-06 07:30 |
Regulatory News Service
Galapagos Press Release_RMAT Designation_GLPG5101_NLfinal.pdf
|
Dutch | 290.7 KB | |
| 2025-07-24 06:29 |
Board/Management Information
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Acc…
|
Dutch | 274.4 KB | |
| 2025-07-24 06:29 |
Board/Management Information
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Acc…
|
English | 262.1 KB | |
| 2025-07-24 06:28 |
Board/Management Information
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Gr…
|
English | 248.2 KB | |
| 2025-07-24 06:28 |
Board/Management Information
Galapagos verwelkomt ervaren farmaceutische leidinggevenden Dawn Svoronos en Ja…
|
Dutch | 269.0 KB | |
| 2025-07-24 06:27 |
Interim Report
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter …
|
English | 354.4 KB |
Automate Your Workflow. Get a real-time feed of all Galapagos NV filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Galapagos NV via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-01 | Filius Bart | Board | Other | 15,430 | 537,118.30 EUR |
| 2023-05-01 | Filius Bart | Board | Other | 14,468 | 503,631.08 EUR |
| 2023-05-01 | Manto Michele | Board | Other | 7,715 | 268,559.15 EUR |
| 2023-05-01 | Manto Michele | Board | Other | 6,201 | 215,856.81 EUR |
| 2023-05-01 | Filius Bart | Board | Other | 4,481 | 155,983.61 EUR |
| 2023-05-01 | Filius Bart | Board | Other | 2,787 | 97,015.47 EUR |
| 2023-05-01 | Cnossen Valeria | Board | Other | 2,378 | 82,778.18 EUR |
| 2023-05-01 | Manto Michele | Board | Other | 1,327 | 46,192.87 EUR |
| 2023-05-01 | Manto Michele | Board | Other | 1,281 | 44,591.61 EUR |
| 2023-05-01 | Missotten Annelies | Board | Other | 1,189 | 41,389.09 EUR |
